BMEA Stock Forecast: Biomea Fusion, Inc. Price Predictions for 2026-2027
The median 12-month analyst price target for Biomea Fusion, Inc. is $6. Ticker Nerd's systematic factor model, run across ~4,300 US stocks, ranks it 46 of 100 as at 21 Nov 2026 — in the lower half.
One number for the whole business
Consensus tells you what everyone already believes. The model scores Biomea Fusion, Inc. on its factor families — the same systematic rank behind the Ticker Nerd portfolio.
Percentile across ~4,300 US stocks on Ticker Nerd’s systematic factor model. Higher is better. How the model is built and tested
Growth (75): Sales and profits are climbing, and climbing faster than before.
Momentum (14): The shares have been drifting down relative to others.
Built and run by Aslam Ghouse, an ex-Goldman Sachs systematic trader with 15+ years in markets.
BMEA stock forecast 2026-2027: analyst price targets & predictions
The bullish and bearish analyst opinions on BMEA, reported as data — targets and ratings, the market's view beside the model's.
Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.
Data provided by Twelve Data
| Date | Firm | Action | Rating | Target |
|---|---|---|---|---|
| 14 Oct 2026 | Citizens | Reiterates | Market Outperform | $7.00 |
| 14 Oct 2026 | HC Wainwright & Co. | Reiterates | Buy | $4.00 |
| 7 Oct 2026 | Brookline Capital | Initiates | Buy | $10 |
| 5 May 2026 | Citizens | Initiates | Market Outperform | $9.00 |
| 28 Apr 2026 | D. Boral Capital | Maintains | Buy | $12 |
| 8 Apr 2026 | D. Boral Capital | Maintains | Buy | — |
| 27 Mar 2026 | Citigroup | Maintains | Buy | — |
| 25 Mar 2026 | D. Boral Capital | Maintains | Buy | — |
| 13 Jan 2026 | D. Boral Capital | Maintains | Buy | — |
| 10 Nov 2025 | Citigroup | Maintains | Buy | — |
| 5 Nov 2025 | D. Boral Capital | Maintains | Buy | — |
| 27 Oct 2025 | D. Boral Capital | Maintains | Buy | — |
| 7 Oct 2025 | D. Boral Capital | Maintains | Buy | — |
| 3 Oct 2025 | D. Boral Capital | Maintains | Buy | — |
| 28 Aug 2025 | Jefferies | Initiates | Buy | — |
| 11 Aug 2025 | Citigroup | Maintains | Buy | — |
| 6 Aug 2025 | D. Boral Capital | Maintains | Buy | — |
| 6 Aug 2025 | Scotiabank | Maintains | Sector Outperform | — |
| 21 July 2025 | D. Boral Capital | Maintains | Buy | — |
| 16 July 2025 | Citigroup | Maintains | Buy | — |
Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.
Wall Street targets run 12 to 18 months out. No analyst publishes a 2030 price target for BMEA.
This page is one stock. Monday covers all of them.
BMEA appears in the Radar on the weeks it earns a place.
- Market Radar, every Monday: the week's biggest rank moves across ~4,300 US stocks, and the reason for each.
- The AI build-out map, free: every AI company we track on one page, with the model's Top picks in all four parts.
AI cloud capacity
MSFTAMZNGOOGLORCL
AI chips
NVDAAVGOAMDMU
AI networking and servers
ANETDELLLITECRDO
Data centre power
VRTCEGGEVVST
BMEA vs the S&P 500
Both lines are total return — dividends reinvested — so the comparison is honest on both sides.
Over the twelve months to 20 Nov 2026, Biomea Fusion, Inc. returned −42.2% against +6.9% for the S&P 500, dividends included.
Download this chart as an image — free to reuse; link this page as the source.
Data provided by Twelve Data
BMEA analyst estimate revisions
Not the forecast itself — the direction analysts are revising it. Revision direction is one of the model's factor families.
Financials
A margin means little on its own. Each bar marks where the figure sits across the whole US universe we score.
- Trailing P/E
- —
- Price / sales
- —
- Price / book
- 5.5×
- EV / EBITDA
- —
Cheaper than 16% of US stocks
- Revenue growth (YoY)
- —
- Earnings growth (YoY)
- —
- Gross margin
- —
- Operating margin
- —
- Net margin
- —
- Return on equity
- −192.3%
- Return on assets
- −75.4%
- Dividend yield
- —
Higher than 8% of US stocks
Higher than 4% of US stocks
Bars mark the percentile across the ~4,300 US stocks Ticker Nerd covers, among those reporting the figure.
Key statistics
The headline figures, each with its date. Every row carries its own link — cite it straight from here.
Biomea Fusion, Inc. has a market value of $41.7M and an enterprise value of $15.8M.
Revenue in the twelve months to 30 June 2026: $0.0.
Net income over the same four quarters: −$32.5M.
Free cash flow in the twelve months to 30 June 2026: −$47.2M.
Biomea Fusion, Inc. employs 34 people.
Data provided by Twelve Data
BMEA and its peers
The nearest names by industry and size, scored by the same model — like for like.
Take a look at BMEA’s peer groups, ranked by the model: healthcare stocks · biotech stocks.
Look up any of the roughly 4,300 stocks we score.
The rank is the raw material. Whether the rules would actually own Biomea Fusion, Inc. — and when they’d sell — is the membership. See the Ticker Nerd 20 →
Questions about BMEA
What is the BMEA stock price forecast for 2026-2027?
The median 12-month analyst price target for Biomea Fusion, Inc. is $6, with estimates ranging from $4 to $10. These are third-party analyst estimates, not Ticker Nerd forecasts, and they are frequently wrong.
Is BMEA stock a buy right now?
Of the 7 analysts covering Biomea Fusion, Inc., 6 rate it a Buy, 0 a Hold and 1 a Sell. Ticker Nerd's systematic factor model ranks Biomea Fusion, Inc. 46 out of 100 across roughly 4,300 US stocks as at 21 Nov 2026. None of this is personal advice — it does not consider your circumstances.
How does Ticker Nerd's model rank BMEA?
As at 21 Nov 2026, Biomea Fusion, Inc. ranks 46 out of 100 on Ticker Nerd's systematic factor model — a percentile across roughly 4,300 US stocks, built from its factor families. Its strongest factor family is Growth (75 of 100).
Will BMEA stock go up?
No one can know that. What the data says: the median 12-month target from 7 analysts is $6, and Ticker Nerd's factor model ranks Biomea Fusion, Inc. 46 out of 100 as at 21 Nov 2026. Analyst targets are third-party estimates and frequently wrong; none of this is personal advice.
What is the BMEA stock forecast for 2030?
No analyst covering Biomea Fusion, Inc. publishes a 2030 price target — Wall Street targets run 12 to 18 months out. Sites quoting a 2030 price for BMEA are extrapolating price history, which says nothing about the business. The furthest attributed numbers are the current analyst targets: $4 to $10 over the next 12 months.
How has BMEA stock performed over the past year?
Biomea Fusion, Inc. returned -42.2% over the 12 months to 20 Nov 2026, with dividends reinvested. Past performance does not indicate future returns.
What does Biomea Fusion, Inc. do?
Biomea Fusion Inc. is a clinical-stage biopharmaceutical company focused on developing oral small-molecule therapies for diabetes, obesity, and other metabolic diseases. Its current pipeline centers on icovamenib, a menin inhibitor being studied across multiple diabetes programs, and BMF-650, an oral GLP-1 receptor agonist in development for obesity.
About Biomea Fusion, Inc.
Biomea Fusion Inc. is a clinical-stage biopharmaceutical company focused on developing oral small-molecule therapies for diabetes, obesity, and other metabolic diseases. Its current pipeline centers on icovamenib, a menin inhibitor being studied across multiple diabetes programs, and BMF-650, an oral GLP-1 receptor agonist in development for obesity. The company’s work is built around covalent chemistry and precision drug design, with an emphasis on therapies intended to address biologically defined patient groups. Biomea Fusion Inc. also explores applications in genetically defined cancers through its broader small-molecule research platform. Headquartered in San Carlos, California, Biomea Fusion Inc. plays a role in the biopharmaceutical market as a developer of investigational treatments aimed at challenging endocrine and metabolic conditions.
CEO Dr. Michael J. M. Hitchcock Ph.D. · 34 employees · United States · https://biomeafusion.com